MedTrace Logo

Neurocytotron on Cerebral Palsy

NCT03743623 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2025-02-13

No results posted yet for this study

Summary

This is a randomized, double-blinded, two-arm, placebo-controlled clinical study. The enrollment will be randomized 1:1 to Neurocytotron treatment or mock treatment (placebo).

Upon the completion of the study period, the placebo group will receive treatment, if the study results show benefits to patients.

Conditions

  • Cerebral Palsy

Interventions

DEVICE

Neurocytotron

Neurocytotron utilizes a combination of instantaneous magnetic field and low-spectrum radiofrequency waves for therapeutic purpose. Its working principle is based on the theory of magnetic resonance.

DEVICE

Placebo

Same treatment procedures without being actually exposed to electromagnetic waves and magnetic field

Sponsors & Collaborators

  • KCRN Research, LLC

    collaborator INDUSTRY

  • Neurocytonix, Inc.

    lead INDUSTRY

Principal Investigators

  • J. Roberto Trujillo, MD, ScD · Neurocytonix, Inc.

  • Lorenzo R Morales Mancías, MD · NeuroCytonix México

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
8 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-22
Primary Completion
2022-12-15
Completion
2023-03-22

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03743623 on ClinicalTrials.gov